We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bioheart and PharmaCell Open GMP Lab Facility in Europe
News

Bioheart and PharmaCell Open GMP Lab Facility in Europe

Bioheart and PharmaCell Open GMP Lab Facility in Europe
News

Bioheart and PharmaCell Open GMP Lab Facility in Europe

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bioheart and PharmaCell Open GMP Lab Facility in Europe "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bioheart Inc. and PharmaCell have announced the grand opening of a GMP lab facility in Maastricht, The Netherlands. The lab facility is in compliance with EU Good Manufacturing Practices (EU-GMP).

This lab is an advanced research facility that also has GMP cell production capabilities to support research related to Bioheart's adult muscle stem cell technology.

Bioheart has developed MyoCell™, a cell therapy that involves extracting and culturing cells from a patient's own thigh muscle.

These cells are inserted back into the patient's damaged heart region via the MyoCath®, a minimally-invasive injection-catheter system.

"We are excited about the opening of this GMP facility that will support our research," said Howard J. Leonhardt, Chairman and CEO of Bioheart.

"We chose the Maastricht region due to its highly educated workforce and its ideal location with close proximity to top research institutes such as the University of Maastricht," he added.

Advertisement